Company Summary
Neuro-Bio is a development-stage biopharmaceutical company focused on developing novel, effective therapeutics for neurodegenerative disorders including Alzheimer’s, Parkinson’s and Motor Neuron Diseases.
Year Founded: 2013
Key Executives:
Baroness Susan Greenfield, Founder & CEO
Sara Garcia-Rates, Operations Director
Aptamer Group plc has announced the successful adaptation of the Optimer-based test for Alzheimer’s disease into...
Read moreNeuro-Bio’s CEO, Baroness Susan Greenfield, will lead the inaugural session at the upcoming WeMind International Forum...
Read moreResearchers at Neuro-Bio Ltd in collaboration with an international team of clinicians and neuroscientists have published...
Read moreAptamer Group plc, the developer of novel Optimer binders, announces the second phase of its on-going partnership with Neuro-Bio,...
Read moreAptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences...
Read moreNeuro-Bio is ready to move to human trials using a radical approach that targets neurodegeneration long...
Read moreBritish scientists believe they may have discovered the first effective treatment for dementia. Researchers at Neuro-Bio say...
Read moreBaroness Susan Greenfield is, among other things, a scientist, author, broadcaster, member of the House of...
Read moreWe are pleased to announce that Neuro-Bio is the latest company to join the Kairos portfolio,...
Read more